ARS Pharmaceuticals, Inc. (SPRY)

NGM – Real Time Price. Currency in USD

8.63

+0.03 (0.35%)

At close: May 12, 2026, 4:00 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

84M

89M

30K

Cost of goods sold

-20M

-1M

-73K

-319K

Gross Profit

64M

88M

-43K

997K

Operating expenses (excl. COGS)

-243M

-91M

-67M

-37M

Operating Income

-179M

-3M

-68M

-36M

Non-operating income, total

11M

13M

834K

Pretax income

-171M

-54M

-35M

Equity in earnings

Taxes

80K

-288K

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

-171M

-54M

-35M

ARS Pharmaceuticals, Inc. (SPRY)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ARS Pharmaceuticals, Inc. (SPRY)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

ARS Pharmaceuticals, Inc. (SPRY)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ARS Pharmaceuticals, Inc. (SPRY)

Income Statement (Annual)

Income Statement (Annual)